# A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease

> **NCT05687890** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Biocity Biopharmaceutics Co., Ltd.** · enrollment: 255 (actual)

## Conditions studied

- Diabetic Kidney Disease
- IgA Nephropathy

## Interventions

- **DRUG:** Placebo of SC0062
- **DRUG:** SC0062 low dose
- **DRUG:** SC0062 medium dose
- **DRUG:** SC0062 high dose

## Key facts

- **NCT ID:** NCT05687890
- **Lead sponsor:** Biocity Biopharmaceutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-23
- **Primary completion:** 2024-11-30
- **Final completion:** 2025-04
- **Target enrollment:** 255 (ACTUAL)
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05687890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05687890, "A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05687890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*